DDInter1397 DDInter1818
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Paroxetine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Tirofiban
Paroxetine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tirofiban
Paroxetine {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Icosapent
Icosapent {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tirofiban
Paroxetine {u} (Compound) downregulates {v} (Gene) HSPD1
HSPD1 {u} (Gene) is associated with {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Tirofiban
Paroxetine {u} (Compound) upregulates {v} (Gene) MAP1LC3B
MAP1LC3B {u} (Gene) is associated with {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Tirofiban
Paroxetine {u} (Compound) downregulates {v} (Gene) HSPD1
HSPD1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Paroxetine {u} (Compound) downregulates {v} (Gene) HSPD1
HSPD1 {u} (Gene) is downregulated by {v} (Compound) Clopidogrel
Clopidogrel {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is bound by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tirofiban
Paroxetine {u} (Compound) downregulates {v} (Gene) MIF
MIF {u} (Gene) is regulated by {v} (Gene) ITGB3
ITGB3 {u} (Gene) is bound by {v} (Compound) Tirofiban
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tirofiban
Paroxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Tirofiban (Compound)
Paroxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban
Paroxetine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Icosapent (Compound) and Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban
Paroxetine (Compound) downregulates HSPD1 (Gene) and HSPD1 (Gene) is associated with coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Tirofiban (Compound)
Paroxetine (Compound) upregulates MAP1LC3B (Gene) and MAP1LC3B (Gene) is associated with coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Tirofiban (Compound)
Paroxetine (Compound) downregulates HSPD1 (Gene) and HSPD1 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Tirofiban
Paroxetine (Compound) downregulates HSPD1 (Gene) and HSPD1 (Gene) is downregulated by Clopidogrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Tirofiban
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is bound by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban
Paroxetine (Compound) downregulates MIF (Gene) and MIF (Gene) is regulated by ITGB3 (Gene) and ITGB3 (Gene) is bound by Tirofiban (Compound)
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban